New Delhi, April 29 (IANS) A team of Brazilian researchers has developed an innovative CAR-T cell therapy that showed positive results in patients with a refractory type of lymphoma — cancer in lymph nodes, spleen, and bone marrow.
HSP-CAR30 is the first European CAR-T30 study to successfully complete its initial phase.
The results of the Phase I trial, published in the journal Blood, trial revealed that the new therapy which targets the CD30 protein has shown high efficacy in patients with refractory CD30+ lymphoma.
The therapy also promotes the expansion of memory T cells, leading to long-lasting responses and improved clinical outcomes in treated patients.
“The most remarkable aspect is the 100 per cent overall response rate, which is extremely rare in patients who have undergone multiple lines of treatment. Additionally, 50 per cent of patients achieved complete remission, meaning the disease was undetectable in imaging studies and clinical analyses,” said Dr. Javier Briones, Head of the Hematological Oncology at the Sant Pau Research Institute (IR Sant Pau).
About 60 per cent of patients who achieved a complete response remained in remission with no signs of relapse after a median follow-up of 34 months.
“This is crucial,” Briones said, “because it indicates that the persistence of CAR-T cells in the body has a real and lasting impact on the disease, which is precisely what we aim for with this type of therapy.”
While CAR-T cell therapies have emerged as a promising alternative for treating B-cell leukemias and lymphomas, their application to CD30+ lymphomas has been limited due to the lack of persistence of modified cells and the high relapse rate among patients.
The Phase I trial involved 10 patients with relapsed or refractory classical Hodgkin lymphoma or CD30+ T-cell lymphoma, yielding highly positive results.
No dose-limiting toxicities were detected.
One of the most significant findings of the study was the high in vivo persistence of CAR30+ cells, which remained detectable in 60 per cent of evaluable patients one year after infusion.
–IANS
rvt/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
